Overview

Womb to Therapy

While the main focus of drug research in the last few decades has been on disease pathogenesis and identifying molecules that would interrupt such pathogenesis, Genervon Biopharmaceuticals took an alternative “womb to therapy” approach and focused on discovering master regulators that play significant roles in embryonic development. Genervon hypothesized that such entities, being integral components of human fetal development, must be able to correct inadvertent errors in that development and thus be life sustaining and potentially therapeutic. Embryonic development is incredibly intricate and yet is accurately repeated with remarkable consistency.

Throughout the embryonic development process, there are crucial master regulators that oversee cell proliferation/apoptosis, differentiation, repair, inflammation/anti-inflammation, and overall developmental balance. Genervon’s core insight is that proteins that participate in the regulation of the embryonic system's development are likely to be multi-functional master regulators that have neurological and neurovascular protective qualities.

The Discovery

Motoneuronotrophic Factor (MNTF) was first discovered by Genervon’s scientists that play significant roles in embryonic development. MNTF is a neurotrophic molecule that binds on very specific receptors of the nervous system. It is an integral component of human fetal development. It is able to correct inadvertent errors in that development and thus be life sustaining and potentially therapeutic.

Throughout the embryonic development process, there are crucial regulatory pathways that oversee cell proliferation/apoptosis, differentiation, repair, inflammation/anti-inflammation, and overall developmental balance. MNTF is a specific master regulator that participates in regulating embryonic nervous system development. It is likely such a multi-functional master regulator that will have neurological protective qualities.

Human Fetal Development

Genervon discovered and reported that the human gene encoding MNTF is located on chromosome 16q22. The gene is expressed in human fetal Multiple Tissue cDNA (MTC) panels including thymus, liver, kidney, brain, lung, heart, and skeletal muscle. The potential functional significance of MNTF is that it may be an integral component of human fetal development, especially during the first trimester. We studied the developing chorionic villi of human placentas during pregnancy with the MNTF monoclonal antibody in immunohistochemical studies. The results revealed that the relative amount of natural MNTF in the placenta varied with gestational ages. It rises rapidly during the sixth to ninth weeks, peaks at the ninth week, and then declines progressively to minimal levels at the terminal week age. It is expressed in very low level in adult human MTC panels.

Stem Cell Differentiation

Stem cell studies at Johns Hopkins Medical Center showed that synthetic MNTF can effectively differentiate embryonic stem cells in vitro into motor neurons.

Nerve Regeneration

Synthetic MNTF promotes in vitro motor neuron proliferation in a dose-dependent fashion. In peripheral nervous system (PNS) studies at Johns Hopkins, MNTF also promoted motor neuron regeneration across an 8mm gap in the rat sciatic nerve in a dose-dependent fashion. In another study, rat femoral nerves were transected and sutured, and femoral cutaneous and muscle branches were labeled. Synthetic MNTF promoted correct reinnervation of muscle nerves by motor neurons at concentrations as low as 10-5M. Thus, it appeared that MNTF plays an important role during the embryonic development of the nervous system and selectively promotes motoneurons regeneration in adulthood.


 
Copyright © 2017 Genervon Biopharmaceuticals, LLC. All rights reserved. All other trademarks or trade names are the property of their respective holders.